PM

Defensive

Philip Morris International

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2007–2025(19yr)

Revenue

Net Income

Free CF

Metric	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$55.2B	$63.6B	$62.1B	$67.7B	$76.3B	$77.4B	$80.0B	$80.1B	$73.9B	$26.7B	$28.7B	$29.6B	$29.8B	$28.7B	$31.4B	$31.8B	$35.2B	$37.9B	$40.6B	+7.3%
Gross Profit	$14.1B	$16.4B	$16.0B	$17.5B	$20.4B	$21.0B	$20.8B	$19.3B	$17.4B	$17.3B	$18.3B	$18.9B	$19.3B	$19.1B	$21.4B	$20.4B	$22.3B	$24.5B	$27.3B	+11.1%
Gross Margin	25.5%	25.7%	25.8%	25.8%	26.7%	27.1%	26.0%	24.1%	23.6%	64.8%	63.7%	63.7%	64.7%	66.7%	68.1%	64.1%	63.3%	64.8%	67.1%	+2.3pp
Operating Income	$8.9B	$10.2B	$10.0B	$11.2B	$13.3B	$13.8B	$13.5B	$11.7B	$10.6B	$10.8B	$11.5B	$11.4B	$10.5B	$11.7B	$13.0B	$12.2B	$11.6B	$13.4B	$14.9B	+11.1%
Operating Margin	16.1%	16.1%	16.2%	16.5%	17.5%	17.9%	16.9%	14.6%	14.4%	40.5%	40.0%	38.4%	35.3%	40.7%	41.3%	38.6%	32.9%	35.4%	36.6%	+1.3pp
Net Income	$6.0B	$6.9B	$6.3B	$7.3B	$8.6B	$8.8B	$8.6B	$7.5B	$6.9B	$7.0B	$6.0B	$7.9B	$7.2B	$8.1B	$9.1B	$9.0B	$7.8B	$7.1B	$11.3B	+60.8%
Net Margin	10.9%	10.8%	10.2%	10.7%	11.3%	11.4%	10.7%	9.4%	9.3%	26.1%	21.0%	26.7%	24.1%	28.1%	29.0%	28.5%	22.2%	18.6%	27.9%	+9.3pp
Free Cash Flow	$4.5B	$6.8B	$7.2B	$8.7B	$9.6B	$8.4B	$8.9B	$6.6B	$6.9B	$6.9B	$7.4B	$8.0B	$9.2B	$9.2B	$11.2B	$9.7B	$7.9B	$10.8B	$10.7B	-1.0%
FCF Margin	8.1%	10.7%	11.5%	12.9%	12.6%	10.8%	11.2%	8.2%	9.3%	25.9%	25.6%	27.1%	31.0%	32.1%	35.7%	30.6%	22.4%	28.4%	26.2%	-2.2pp
EPS (Diluted)	$2.86	$3.31	$3.24	$3.92	$4.85	$5.17	$5.26	$4.76	$4.42	$4.48	$3.88	$5.08	$4.61	$5.16	$5.83	$5.81	$5.02	$4.52	$7.26	+60.6%

Total Debt$45.1B

Cash & Equiv.$4.9B

Net Debt$40.3B

3 min read

1. THE BIG PICTURE

Philip Morris International is no longer a traditional tobacco company in decline; it is a high-margin nicotine technology business currently outgrowing its consumer staple peers. By securing "first-ever" FDA authorizations for its heat-not-burn and oral nicotine products, Philip Morris International has built a regulatory moat that its competitors—particularly Altria, which saw revenues decline 3.1%—have failed to match.

2. WHERE THE RISKS HIT HARDEST

Philip Morris International’s "World-class scientific assessment capabilities" (10-K Item 1) are directly threatened by "Regulatory Initiatives" like plain packaging and advertising bans (10-K Item 1A). If governments commoditize the category, Philip Morris International loses the ability to communicate the "scientific substantiation" it spent $16 billion to build, effectively neutralizing its primary competitive advantage. Furthermore, the cash flows from the "Combustible Product" segment are essential to fund the transition; however, as cigarette volumes fell 2.2% in the most recent quarter (8-K), the window to complete this pivot is narrowing. Any acceleration in the decline of traditional cigarettes before smoke-free products reach full global scale would create a capital shortfall for its "smoke-free future" (10-K Item 1).

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a company operating at a different velocity than the broader consumer sector. Philip Morris International leads its peer group in revenue growth at 7.3%, significantly ahead of Procter & Gamble (+0.3%) and Coca-Cola (+1.9%) (Yahoo Finance). This growth is paired with a 67.2% gross margin—the highest in its peer group—which provides the necessary cushion to absorb the $1.4 billion to $1.6 billion in annual capital expenditures required to scale its smoke-free infrastructure (XBRL). While net revenue grew 6.8% in the fourth quarter of 2025, reported diluted EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric surged 100% to $1.37 (8-K). This divergence suggests that the smoke-free transition is becoming more efficient, as Philip Morris International has already delivered its three-year operating income and EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric targets in just two years (8-K).

4. IS IT WORTH IT AT THIS PRICE?

At 18.7x forward earnings, Philip Morris International trades at a modest 12% discount to the peer median of 21.3x (Yahoo Finance). This discount is difficult to justify given that Philip Morris International leads all five peers in revenue growth. According to the CAPM analysis, the current price implies a long-term growth rate of just 1.3%. This is a low bar for a company that grew its smoke-free business by 12% in the most recent quarter (8-K). If Philip Morris International continues to grow at a pace closer to GDP (2.5%), the justified multiple would rise to 24.0x. The primary factor keeping the valuation suppressed is likely the $39.7 billion in net debt and the "geopolitical instability" related to its Russian business, which remains a candidate for deconsolidation (10-K Item 1A).

5. WHAT WOULD CHANGE THIS VIEW?

Constructive if the FDA grants additional Modified Risk Tobacco Product (MRTP) authorizations for the U.S. launch of IQOS, which would validate Philip Morris International’s "Scientific Substantiation" advantage in the world's most profitable market.
Cautious if smoke-free net revenue growth (currently 12%) decelerates toward the combustible growth rate (3.2%), signaling that the transition is hitting a ceiling in established markets.

6. BOTTOM LINE

Structural Advantage: A first-mover regulatory advantage backed by a $16 billion scientific IP portfolio and the world’s best-selling international cigarette brand. Bottom Line: Philip Morris International is a high-growth outlier in a defensive sector, and its current valuation discount fails to account for its successful pivot away from combustible tobacco.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Smoke-Free Product (SFP) Commercialization: Philip Morris International may fail to grow its SFP business if regulators prohibit or restrict these products, or if competitors successfully lobby for inequitable regulations that ignore the scientific evidence supporting Philip Morris International’s products.
Combustible Product Decline: The consumption of tax-paid cigarettes is falling due to health concerns, increased pricing, and social stigma, which threatens the cash flows and profitability required to fund Philip Morris International's transition to smoke-free alternatives.
Regulatory Initiatives: Governments are increasingly considering measures such as plain packaging, advertising bans, and generation sales bans, which could commoditize tobacco products and impede Philip Morris International's ability to convert adult smokers to its SFP portfolio.
United States Regulatory Environment: The commercialization of IQOS and ZYN in the U.S. is dependent on FDA authorizations, which are subject to strict requirements and could be revoked if there is significant uptake of these products among youth or non-nicotine users.
Geopolitical Conflict (Russia and Ukraine): The war in Ukraine poses risks to assets in Russia (which accounted for approximately 9% of total cigarette and heated tobacco unit shipment volume and 6% of net revenues in 2025) and Ukraine (2% of volume and 1% of net revenues), including potential nationalization or forced divestment.

2. Company-Specific Risks

Predictability of SFP Performance: Unlike the mature cigarette business, the SFP category is relatively new, making financial results less predictable and subject to volatility based on the pace of adult smoker adoption.
Reliance on Single-Source Production: The ZYN production facility in Kentucky supplies substantially all of Philip Morris International's capacity for U.S. sales; any prolonged disruption at this site could limit the ability to meet customer demand.
Intellectual Property Disputes: Philip Morris International faces the risk that third parties may claim infringement of their intellectual property, which could impede the ability to manufacture or sell SFPs and divert management attention.
Wellness Business Risks: The research and development of medical and pharmaceutical cannabinoids is exploratory and subject to a complex, evolving regulatory environment that could result in criminal, civil, or tax liability.

3. Regulatory/Legal Risks

Litigation Exposure: Philip Morris International is subject to significant tobacco-related litigation, with claims in some cases ranging into the billions of U.S. dollars.
Governmental Investigations: Philip Morris International faces ongoing investigations regarding contraband shipments, unlawful pricing, underpayment of taxes, and misleading usage of product descriptors.
Taxation Regimes: Changes in tax laws, including the OECD’s "Pillar Two" global minimum tax framework, could increase the effective tax rate and reduce net earnings.
Data Privacy and AI Regulation: Failure to comply with complex, varying global privacy and artificial intelligence laws could result in substantial fines, legal challenges, and reputational harm.

4. Financial Impact Map

SFP Commercialization Risk → Net Revenues and Profitability → Failure to grow SFPs or regulatory restrictions on them would materially adversely impact future growth prospects.

Combustible Product Decline → Cash Flows and Profitability → Reduced volumes from cigarette declines directly impact the funds available for the smoke-free transformation.

Regulatory Initiatives → Net Revenues → Requirements that commoditize products or impede access to SFPs could lead to a significant decrease in demand for brands.

U.S. Regulatory Environment → Results of Operations and Cash Flows → Failure to manage compliance or loss of FDA authorizations for IQOS or ZYN would have a material adverse effect on U.S. financial results.

Geopolitical Conflict (Russia/Ukraine) → Assets and Net Earnings → Potential divestment or deprivation of rights in Russian assets would likely result in material impairment charges and potential deconsolidation.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
8-K	Feb 2026	—
10-K	Feb 2026	Dec 2025
10-Q	Oct 2025	Sep 2025
14A	Mar 2025	—